

Vet Biotechnology Ltd

ACN 105 577 017

Appendix 3 - Supplementary Information

Reconciliation of cash

Reconciliation of cash at the end of the period (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows.

		Current period \$A'000	Previous corresponding period \$A'000
8.1	Cash on hand and at bank	297,598	65,060
8.2	Deposits at call	-	-
8.3	Bank overdraft	-	-
8.4	Other (provide details)	-	-
8.5	Total cash at end of period (item 7.25)	297,598	65,060

Ratios

		Current period	Previous corresponding period
Profit before abnormals and tax/sales			
9.1	Consolidated operating profit (loss) before abnormal items and tax (items 1.4) as a percentage of sales revenue (items 1.1)	(2773.73%)	39.98%
Profit after tax/equity interests			
9.2	Consolidated operating profit (loss) after tax attributable to members (item 1.10) as a percentage of equity (similarly attributable) at the end of the period (item 4.34)	(28.44%)	11.86%

Issued and listed securities

Description includes rate of interest and any redemption or conversion rights together with prices and rates.

Category of securities		Number issued	Number listed	Par value (cents)	Paid-up value (cents)
18.1	Preference securities (description)	N/A	N/A	N/A	N/A
18.2	Issued during current period	N/A	N/A	N/A	N/A
18.3	Ordinary securities	10,429,759	10,429,759		
18.4	Issued during current period	2,129,666	2,129,666		
18.5	Convertible debt securities (description and conversion factor)	N/A	N/A	N/A	N/A
18.6	issued during current period	N/A	N/A	N/A	N/A
18.7	Options (description and conversion factor)	10,429,759	10,429,759	Exercise price	Expiry date
				30 cents	30/06/2011
18.8	Issued during current period	2,129,666	2,129,666	30 cents	30/06/2011
18.9	Exercised during current period	-	-		
18.10	Expired during current period	-	-		
18.11	Debentures (totals only)	N/A	N/A		
18.12	Unsecured Notes (totals only)	N/A	N/A		